Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry O Fischmann

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Bioorganic & Medicinal Chemistry Letters|July 20, 2017
Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritisSobhana Babu Boga, Abdul-Basit Alhassan, Jian Liu, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2017
Discovery of novel BTK inhibitors with carboxylic acidsXiaolei Gao, James Wang, Jian Liu, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2Kamil Paruch, Michael P Dwyer, Carmen Alvarez, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid ArthritisJian Liu, Deodial Guiadeen, Arto Krikorian, et al.
Bioorganic & Medicinal Chemistry Letters|May 15, 2017
Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammationGraham F Smith, Michael D Altman, Brian Andresen, et al.
Nature|September 30, 2015
Selective small-molecule inhibition of an RNA structural elementJohn A Howe, Hao Wang, Thierry O Fischmann, et al.
Journal for Immunotherapy of Cancer|September 13, 2022
Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapyLars Guelen, Thierry O Fischmann, Jerelyn Wong, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2020
Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutesJian Liu, Deodial Guiadeen, Arto Krikorian, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Bioorganic & Medicinal Chemistry Letters|July 20, 2017
Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritisSobhana Babu Boga, Abdul-Basit Alhassan, Jian Liu, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2017
Discovery of novel BTK inhibitors with carboxylic acidsXiaolei Gao, James Wang, Jian Liu, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2Kamil Paruch, Michael P Dwyer, Carmen Alvarez, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid ArthritisJian Liu, Deodial Guiadeen, Arto Krikorian, et al.
Bioorganic & Medicinal Chemistry Letters|May 15, 2017
Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammationGraham F Smith, Michael D Altman, Brian Andresen, et al.
Nature|September 30, 2015
Selective small-molecule inhibition of an RNA structural elementJohn A Howe, Hao Wang, Thierry O Fischmann, et al.
Journal for Immunotherapy of Cancer|September 13, 2022
Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapyLars Guelen, Thierry O Fischmann, Jerelyn Wong, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2020
Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutesJian Liu, Deodial Guiadeen, Arto Krikorian, et al.
Pageof 3